Harrow, Inc. $HROW Shares Purchased by Woodmont Investment Counsel LLC

Woodmont Investment Counsel LLC boosted its holdings in Harrow, Inc. (NASDAQ:HROW) by 2.4% during the second quarter, HoldingsChannel reports. The fund owned 106,213 shares of the company’s stock after buying an additional 2,520 shares during the period. Woodmont Investment Counsel LLC’s holdings in Harrow were worth $3,244,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in HROW. Voya Investment Management LLC lifted its holdings in Harrow by 4,035.5% in the first quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock valued at $10,147,000 after acquiring an additional 372,237 shares during the last quarter. Nuveen LLC acquired a new position in Harrow in the first quarter valued at approximately $2,046,000. Braidwell LP lifted its holdings in Harrow by 5.5% in the first quarter. Braidwell LP now owns 956,839 shares of the company’s stock valued at $25,452,000 after acquiring an additional 49,800 shares during the last quarter. Royce & Associates LP lifted its holdings in Harrow by 12.0% in the first quarter. Royce & Associates LP now owns 327,096 shares of the company’s stock valued at $8,701,000 after acquiring an additional 35,006 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Harrow by 89.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company’s stock valued at $2,078,000 after acquiring an additional 29,262 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on HROW shares. Lake Street Capital upped their price target on Harrow from $42.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Craig Hallum upped their price target on Harrow from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. William Blair started coverage on Harrow in a research note on Tuesday, June 10th. They set an “outperform” rating on the stock. BTIG Research restated a “buy” rating and set a $63.00 price target on shares of Harrow in a research note on Wednesday, September 24th. Finally, B. Riley restated a “buy” rating and set a $74.00 price target (up from $70.00) on shares of Harrow in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $68.50.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $45.43 on Monday. Harrow, Inc. has a 52 week low of $20.85 and a 52 week high of $59.23. The company has a 50-day moving average price of $39.56 and a 200 day moving average price of $32.26. The company has a market cap of $1.68 billion, a P/E ratio of -181.72 and a beta of 0.27. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The company had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow has set its FY 2025 guidance at EPS. Research analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.